1.	Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: RTOG 1216, NCI-2013-00500, U10CA021661, NCT01810913
2.	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00507, E1305, CDR0000582533, U10CA021115, ECOG-E1305, NCT00588770
3.	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675520, NCCTG-N09C6, N09C6, NCT01156142
4.	Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 06-121, 1R21CA130241-01A1, NCT00903461
5.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
6.	E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-702, 2011-000773-31, NCT01332266
7.	Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage III-IV Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02009, A091101, U10CA031946, N01CM62201, NCT01711541
8.	Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors Phase: Phase II Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: HSC-MS-04-259, NCT00178698
9.	Preoperative Treatment With Cetuximab and/or IMC-A12 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0342, NCT00957853
10.	Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-083, NCT00968435
11.	A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090214, 09-C-0214, NCT00978250
12.	Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 15309, NCI-2009-01492, NCT01044433
13.	A Study in Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13420, I4E-MC-JXBB, NCT01063075
14.	Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCI 06-093, NCT01104922
15.	Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000686072, RTOG-1008, NCT01220583
16.	Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and ovwe Sponsor: Other Protocol IDs: FER-HN-027, NCI-2011-00272, NCT01316757
17.	Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 7674, NCI-2012-00892, NCT01613768
18.	Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CTRC 11-37, HSC20120130H, NCT01634880
19.	Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01640, 12-1359, N01CM00071, NCT01696955
20.	Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 05-0108-04, P30CA023074, UARIZ-05-0108-01, UARIZ-HSC0529, UARIZ-SRC17855, LILLY-UARIZ-05-0108-01, 05-0108-01, NCT01172028
21.	Four Doses of MAGE Vaccine for Patients With Squamous Cell Carcinoma of the Head and Neck Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: HP-41372, UMGCC 0804, NCT00704041
22.	Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000635094, BUMC-H-26649, H-26649, NCT00851253
23.	Dose-escalation Study of Oral CX-4945 Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C4-08-001, NCT00891280
24.	Sirolimus and Cetuximab in Advanced Malignancies Phase: Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2009-0226, NCT00940381
25.	Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: M06-10083, NCT01017185